Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Over 95% of babies now diagnosed with SMA are treated with Zolgensma gene therapy, per Daniel Grant, vice president for ...

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

We need a different way to pay for these “miracle” drugs. One option is to have them paid for on an annual basis, spreading the cost over the patient’s estimated lifespan, with payment to stop if the ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...